1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow Recurrent Primitive Neuroectodermal Tumor: new trials by email Literature Review of Recurrent Primitive Neuroectodermal Tumor trials Research Report on Recurrent Primitive Neuroectodermal Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Bevacizumab, Irinotecan Hydrochloride, Temozolomide - Central Nervous System Neoplasm, Pineoblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 108 | 2010-11-22 | 2021-07-23 |
Central Nervous System Neoplasms (1) · Medulloblastoma (1) · Neuroectodermal Tumors, Primitive (1) · Neuroectodermal Tumors, Primitive, Peripheral (1) · Pinealoma (1)
Brain Diseases (1) · Brain Neoplasms (1) · Central Nervous System Diseases (1) · Glioma (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Nerve Tissue (1) · Neoplasms, Neuroepithelial (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1) · Neuroectodermal Tumors (1)
Bevacizumab (1) · Disulfides (1) · Immunoglobulin G (1) · Irinotecan (1) · Temozolomide (1)
National Cancer Institute (NCI) (1)
Australia (1) · Canada (1) · New Zealand (1) · Puerto Rico (1) · United States (1)
Adam S Levy (1)
U10CA098543 (1), U10CA180886 (1)